-$32.7M
Net Activity
Institutions Holding
76
Popularity Rank
#5077
Avg Weight
0.09%
Total Value
$32.6M
76 institutions currently hold RANI, with 31 net buyers and 25 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
25
Net Buying Institutions
31
Top 5 by Value
+$4.2M
Total Buy Value
$15.1M
Total Sell Value
31
Net Buyers
25
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Rani Therapeutics today appointed Nicholas M. Maestas as its new Chief Financial Officer, effective June 29, 2026. Maestas, who previously served as CFO of Tempest Therapeutics, replaces Svai Sanford. He will receive a $500,000 base salary, a target annual bonus of 75% of salary, and an option to buy 2 million shares that vest over four years. The company also set aside 5.5 million shares under a new equity inducement plan for future hires.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter